Is there a hashtag for STEM internships?
Merck is accepting applications for internships in cell biology and assay development, immunogenicity, protein metabolism, biostatistics, vaccine communications, DMPK, and discovery and process chemistry.
Merck is accepting applications for internships in cell biology and assay development, immunogenicity, protein metabolism, biostatistics, vaccine communications, DMPK, and discovery and process chemistry.
Merck is accepting applications for its 2026 Future Talent Program - these are internships and co-ops in a variety of areas including drug discovery, vaccines, clinical trials, biostatistics, epidemiology, HEOR, data science, regulatory affairs, and more
#chemsky 🧪⚗️
jobs.merck.com/us/en/search...
#chemsky 🧪⚗️
jobs.merck.com/us/en/search...
Your job search results | Merck Careers
jobs.merck.com
November 5, 2025 at 10:15 PM
Is there a hashtag for STEM internships?
Merck is accepting applications for internships in cell biology and assay development, immunogenicity, protein metabolism, biostatistics, vaccine communications, DMPK, and discovery and process chemistry.
Merck is accepting applications for internships in cell biology and assay development, immunogenicity, protein metabolism, biostatistics, vaccine communications, DMPK, and discovery and process chemistry.
September: #MuscularDystrophy Awareness Month
🔹DMD | PMO exon skipping; PPMOs & AOCs aim to improve muscle delivery
🔹DM1 | ASOs & AOCs target DMPK RNA
🔹OPMD | Gene therapy approaches are under exploration
🔹LGMD | Gene therapy & oligonucleotide approaches are being investigated for selected subtypes
🔹DMD | PMO exon skipping; PPMOs & AOCs aim to improve muscle delivery
🔹DM1 | ASOs & AOCs target DMPK RNA
🔹OPMD | Gene therapy approaches are under exploration
🔹LGMD | Gene therapy & oligonucleotide approaches are being investigated for selected subtypes
September 30, 2026 at 12:00 PM
September: #MuscularDystrophy Awareness Month
🔹DMD | PMO exon skipping; PPMOs & AOCs aim to improve muscle delivery
🔹DM1 | ASOs & AOCs target DMPK RNA
🔹OPMD | Gene therapy approaches are under exploration
🔹LGMD | Gene therapy & oligonucleotide approaches are being investigated for selected subtypes
🔹DMD | PMO exon skipping; PPMOs & AOCs aim to improve muscle delivery
🔹DM1 | ASOs & AOCs target DMPK RNA
🔹OPMD | Gene therapy approaches are under exploration
🔹LGMD | Gene therapy & oligonucleotide approaches are being investigated for selected subtypes
like the models are cool and all but none of that shit made it to the clinic without a bunch of conventional CMC and DMPK
April 21, 2026 at 6:36 AM
like the models are cool and all but none of that shit made it to the clinic without a bunch of conventional CMC and DMPK
Opportunity for #DMPK scientist at Cancer Research UK (Cambridge UK) ref: R032928 | closing 01-Mar-2026 | duration: 1 year #chemsky 🧪
cancerresearchuk.wd3.myworkdayjobs.com/External_Car...
cancerresearchuk.wd3.myworkdayjobs.com/External_Car...
Senior Scientist (DMPK)
200 staff. Limitless Potential. One team. Cancer Research Horizons. Senior Scientist (DMPK) £41,700 - £46,500 plus benefits Department: Therapeutic Innovation, R&I Reports to: Group Leader Locatio...
cancerresearchuk.wd3.myworkdayjobs.com
February 19, 2026 at 1:19 PM
Opportunity for #DMPK scientist at Cancer Research UK (Cambridge UK) ref: R032928 | closing 01-Mar-2026 | duration: 1 year #chemsky 🧪
cancerresearchuk.wd3.myworkdayjobs.com/External_Car...
cancerresearchuk.wd3.myworkdayjobs.com/External_Car...
New #MolTherapy paper: Development of an AAV-delivered microRNA gene therapy for Myotonic Dystrophy Type 1. #Myoblue tinyurl.com/mrjrue3f
Development of an AAV-delivered microRNA gene therapy for Myotonic Dystrophy Type 1
An AAV-mediated gene therapy for myotonic dystrophy type 1 using a novel muscle-tropic
capsid and promoter to express a DMPK-targeting miRNA effectively reduces DMPK expression
and nuclear RNA foci, a...
tinyurl.com
September 4, 2025 at 4:25 PM
New #MolTherapy paper: Development of an AAV-delivered microRNA gene therapy for Myotonic Dystrophy Type 1. #Myoblue tinyurl.com/mrjrue3f
Skeetorial time! Let’s talk early human dose prediction. Not the fancy, need-tons-of-software and a DMPK pro kind. Just the kind that uses some basic algebra. HDP is a unifying concept for med chemists. It’s the master optimization parameter, and it can’t be easily cheated. 1/
a pink background with pills and capsules on it
ALT: a pink background with pills and capsules on it
media.tenor.com
November 23, 2024 at 8:43 PM
Skeetorial time! Let’s talk early human dose prediction. Not the fancy, need-tons-of-software and a DMPK pro kind. Just the kind that uses some basic algebra. HDP is a unifying concept for med chemists. It’s the master optimization parameter, and it can’t be easily cheated. 1/
Exploring DMPK: How Viva Biotech Is Advancing Pharmacology Platforms in Drug Discovery#Shanghai#None#Pharmacokinetics#Viva_Biotech#DMPK
Exploring DMPK: How Viva Biotech Is Advancing Pharmacology Platforms in Drug Discovery
Viva Biotech is innovating drug discovery with an integrated pharmacology platform that encompasses various modalities including small molecules and antibodies.
third-news.com
December 29, 2025 at 6:32 AM
Exploring DMPK: How Viva Biotech Is Advancing Pharmacology Platforms in Drug Discovery#Shanghai#None#Pharmacokinetics#Viva_Biotech#DMPK
Johnson and colleagues report a phase 1–2 trial of del-desiran, an antibody–oligonucleotide conjugate designed to reduce DMPK mRNA, to treat myotonic dystrophy type 1. Full MARINA trial results: nej.md/4tBOFbu
#MedSky #NeuroSky #Genetics
#MedSky #NeuroSky #Genetics
February 19, 2026 at 5:09 PM
Johnson and colleagues report a phase 1–2 trial of del-desiran, an antibody–oligonucleotide conjugate designed to reduce DMPK mRNA, to treat myotonic dystrophy type 1. Full MARINA trial results: nej.md/4tBOFbu
#MedSky #NeuroSky #Genetics
#MedSky #NeuroSky #Genetics
Opportunity for Executive Director #DMPK - Respiratory and Immunology at AstraZeneca (Gothenburg Sweden) ref: R-221587 | closing: 28-Mar-2025 #chemsky 🧪
astrazeneca.wd3.myworkdayjobs.com/Careers/job/...
astrazeneca.wd3.myworkdayjobs.com/Careers/job/...
Executive Director, DMPK - Respiratory and Immunology
About AstraZeneca: AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. Our innovative pipeline o...
astrazeneca.wd3.myworkdayjobs.com
March 17, 2025 at 7:31 AM
Opportunity for Executive Director #DMPK - Respiratory and Immunology at AstraZeneca (Gothenburg Sweden) ref: R-221587 | closing: 28-Mar-2025 #chemsky 🧪
astrazeneca.wd3.myworkdayjobs.com/Careers/job/...
astrazeneca.wd3.myworkdayjobs.com/Careers/job/...
Two opportunities at OpenADMET organization (remote) #ADME #ADMET #DMPK #ML #AI #cheminformatics #DataScience #chemsky 🧪
openadmet.org/jobs/
openadmet.org/jobs/
OpenADMET Jobs
Seeking talented scientists for the OpenADMET Consortium
openadmet.org
January 14, 2025 at 10:24 AM
Two opportunities at OpenADMET organization (remote) #ADME #ADMET #DMPK #ML #AI #cheminformatics #DataScience #chemsky 🧪
openadmet.org/jobs/
openadmet.org/jobs/
Your drug worked perfectly in cells.
Then it failed in clinical trials.
Here's why in vitro success means nothing without understanding DMPK.
Then it failed in clinical trials.
Here's why in vitro success means nothing without understanding DMPK.
December 6, 2025 at 2:45 PM
Your drug worked perfectly in cells.
Then it failed in clinical trials.
Here's why in vitro success means nothing without understanding DMPK.
Then it failed in clinical trials.
Here's why in vitro success means nothing without understanding DMPK.
Access our June Issue of Med Chem Res 2026 here: link.springer.com/journal/44/v... #medicinalchemistry #naturalproducts #drugdiscovery #chemistry #MedChemRes #MedChemResearch #DMPK #rutgersmedchem
June 26, 2026 at 10:26 PM
Access our June Issue of Med Chem Res 2026 here: link.springer.com/journal/44/v... #medicinalchemistry #naturalproducts #drugdiscovery #chemistry #MedChemRes #MedChemResearch #DMPK #rutgersmedchem
DMPK 3′ untranslated repeat expansions in unexplained sudden cardiac death in the young url: academic.oup.com/eurheartj/ar...
DMPK 3′ untranslated repeat expansions in unexplained sudden cardiac death in the young
Sudden cardiac death (SCD) is the unexpected death of a previously healthy individual due to a known or suspected cardiac cause. In our Australian/New Zeal
academic.oup.com
April 8, 2026 at 6:41 AM
DMPK 3′ untranslated repeat expansions in unexplained sudden cardiac death in the young url: academic.oup.com/eurheartj/ar...
Exciting new clinical trial results for del-desiran in #myotonicDystrophy type 1 (DM1) showed an approximate 40% reduction in toxic DMPK mRNA in muscle, with associated improvements in myotonia, strength, and mobility.
Read the press release: prn.to/4u0khrA
Read the press release: prn.to/4u0khrA
February 20, 2026 at 2:51 AM
Exciting new clinical trial results for del-desiran in #myotonicDystrophy type 1 (DM1) showed an approximate 40% reduction in toxic DMPK mRNA in muscle, with associated improvements in myotonia, strength, and mobility.
Read the press release: prn.to/4u0khrA
Read the press release: prn.to/4u0khrA
Exploring Pharmacology Innovations: Viva Biotech's Comprehensive DMPK Solutions#China#Shanghai#Viva_Biotech#Pharmacology#DMPK
Exploring Pharmacology Innovations: Viva Biotech's Comprehensive DMPK Solutions
Viva Biotech's groundbreaking DMPK pharmacology platform integrates diverse drug discovery modalities, facilitating efficient development from small molecules to antibodies.
third-news.com
December 29, 2025 at 6:21 AM
Exploring Pharmacology Innovations: Viva Biotech's Comprehensive DMPK Solutions#China#Shanghai#Viva_Biotech#Pharmacology#DMPK
Congratulations Heide Marika Düvel, Christina Schindler, Christine Maurer, and colleagues at Merck KGaA on their work understanding the optimal ADME properties for bifunctional degraders!
pubs.rsc.org/en/content/a...
pubs.rsc.org/en/content/a...
In vitro and in vivo ADME of heterobifunctional degraders: a tailored approach to optimize DMPK properties of PROTACs©
Proteolysis-targeting chimeras (PROTACs©) have recently emerged as a promising new drug modality. Residing beyond the rule-of-five space, they pose challenges in terms of physicochemical properties. W...
pubs.rsc.org
February 22, 2025 at 8:25 PM
Congratulations Heide Marika Düvel, Christina Schindler, Christine Maurer, and colleagues at Merck KGaA on their work understanding the optimal ADME properties for bifunctional degraders!
pubs.rsc.org/en/content/a...
pubs.rsc.org/en/content/a...
Missed our latest BBB webinar? Good news: it's now available on-demand!
We explore a 3D perfused primary human BBB for disease modeling (such as Stroke & neuroinflammation) and DMPK studies—advancing drug discovery with better physiological relevance.
Watch here: shorturl.at/Dpug0
We explore a 3D perfused primary human BBB for disease modeling (such as Stroke & neuroinflammation) and DMPK studies—advancing drug discovery with better physiological relevance.
Watch here: shorturl.at/Dpug0
March 5, 2025 at 2:42 PM
Missed our latest BBB webinar? Good news: it's now available on-demand!
We explore a 3D perfused primary human BBB for disease modeling (such as Stroke & neuroinflammation) and DMPK studies—advancing drug discovery with better physiological relevance.
Watch here: shorturl.at/Dpug0
We explore a 3D perfused primary human BBB for disease modeling (such as Stroke & neuroinflammation) and DMPK studies—advancing drug discovery with better physiological relevance.
Watch here: shorturl.at/Dpug0
Opportunity for Preclinical #DMPK Design Lead at AstraZeneca (Gothenburg Sweden) ref: R-221079 | closing: 17-Mar-2025 #ADME #AnalChem #MedChem #EUChemJobs #ChemJobs #chemsky 🧪
astrazeneca.wd3.myworkdayjobs.com/Careers/job/...
astrazeneca.wd3.myworkdayjobs.com/Careers/job/...
astrazeneca.wd3.myworkdayjobs.com
March 5, 2025 at 7:31 AM
Opportunity for Preclinical #DMPK Design Lead at AstraZeneca (Gothenburg Sweden) ref: R-221079 | closing: 17-Mar-2025 #ADME #AnalChem #MedChem #EUChemJobs #ChemJobs #chemsky 🧪
astrazeneca.wd3.myworkdayjobs.com/Careers/job/...
astrazeneca.wd3.myworkdayjobs.com/Careers/job/...
🧬 DM1 is a complex genetic disease affecting multiple body systems. A fast, reliable method to measure DMPK & MBNL1 proteins across diverse cell models is described in NARMME: doi.org/10.1093/narm...
@varechavala.bsky.social
#DM1Research #MyotonicDystrophy #MolecularBiology #OAPublication
@varechavala.bsky.social
#DM1Research #MyotonicDystrophy #MolecularBiology #OAPublication
August 19, 2025 at 11:07 AM
🧬 DM1 is a complex genetic disease affecting multiple body systems. A fast, reliable method to measure DMPK & MBNL1 proteins across diverse cell models is described in NARMME: doi.org/10.1093/narm...
@varechavala.bsky.social
#DM1Research #MyotonicDystrophy #MolecularBiology #OAPublication
@varechavala.bsky.social
#DM1Research #MyotonicDystrophy #MolecularBiology #OAPublication
New #CommsMed paper: FORCE platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical models. #DM1 #MyoBlue tinyurl.com/z4jrmaxk
FORCE platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical models - Communications Medicine
Weeden et al. use a method called FORCE to deliver oligonucleotides to muscle and evaluate the platform’s utility in models of myotonic dystrophy. An antisense oligonucleotide targeting DMPK is guided...
tinyurl.com
January 18, 2025 at 6:12 PM
New #CommsMed paper: FORCE platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical models. #DM1 #MyoBlue tinyurl.com/z4jrmaxk
Opportunity in #DMPK at Kymera (Boston USA) 🧪 www.kymeratx.com/gh-jobs/asso...
April 12, 2024 at 6:04 AM
Opportunity in #DMPK at Kymera (Boston USA) 🧪 www.kymeratx.com/gh-jobs/asso...
What kills me is that some pharma companies have separate groups called PKDM and DMPK.
November 10, 2024 at 7:55 AM
What kills me is that some pharma companies have separate groups called PKDM and DMPK.
Spanish study: Characterization of DMPK and MBNL1 expression in cell models of myotonic dystrophy: a platform for drug screening academic.oup.com/narmolmed/ar...
Characterization of DMPK and MBNL1 expression in cell models of myotonic dystrophy: a platform for drug screening
Abstract. Myotonic dystrophy type I (DM1) is caused by CTG repeat expansions in the DMPK gene leading to mRNA toxicity and sequestration of the splicing re
academic.oup.com
November 19, 2025 at 1:58 PM
Spanish study: Characterization of DMPK and MBNL1 expression in cell models of myotonic dystrophy: a platform for drug screening academic.oup.com/narmolmed/ar...